Geron Corp Stock Price, News & Analysis

Geron Corporation (NASDAQ: GERN) announced the grant of non-statutory stock options for 640,550 shares of common stock to new employees. The stock options were issued on February 15, 2023, at an exercise price of $2.69 per share, matching Geron's closing price on that date. Of the options, 595,800 shares will vest over four years, while 44,750 shares are contingent on achieving specific regulatory milestones. This grant complies with Nasdaq Listing Rule 5635(c)(4) and is part of Geron's 2018 Inducement Award Plan. The company focuses on therapies for hematologic malignancies.

Geron Corporation (NASDAQ: GERN) announced the granting of non-statutory stock options to a newly hired employee, totaling 75,730 shares. The options were issued on January 18, 2023, at an exercise price of $3.12 per share, matching the stock's closing price on the grant date. Of these, 70,000 shares have a 10-year term, vesting over four years with an initial 12.5% vesting at six months. The remaining 5,730 shares vest upon achieving certain regulatory milestones. This grant complies with Nasdaq Listing Rule 5635(c)(4) and is part of Geron’s 2018 Inducement Award Plan.

Geron Corporation (Nasdaq: GERN) announced that Dr. John A. Scarlett, Chairman and CEO, will participate in a virtual fireside chat at the B. Riley Securities 3rd Annual Virtual Oncology Conference on January 18 at 1 p.m. ET. A live webcast will be available via the Investor Relations section of Geron's website, with an archived replay accessible for 30 days post-event. Geron is focused on developing therapies for hematologic malignancies, including the first-in-class telomerase inhibitor, imetelstat.

Geron Corporation (NASDAQ: GERN) announced key additions to its senior commercial leadership team as it prepares for the anticipated launch of imetelstat, a first-in-class telomerase inhibitor, in the U.S. for lower risk myelodysplastic syndromes (MDS) in the first half of 2024, pending regulatory approvals. The company reported positive Phase 3 clinical trial results and plans to submit a New Drug Application (NDA) in mid-2023 and a Marketing Authorization Application (MAA) in the EU in late 2023. This strategic hiring aims to ensure successful market access and commercialization efforts.

Geron Corporation (NASDAQ: GERN) has successfully completed a public offering of common stock and pre-funded warrants, generating $227.8 million in gross proceeds. The offering included 68,007,741 shares at a price of $2.45 per share, with an additional 25,000,000 pre-funded warrants. After expenses, the net proceeds are estimated to be around $213.3 million. Geron plans to utilize these funds primarily for the potential commercial launch of imetelstat in the U.S. for lower risk MDS and for general corporate purposes.

Geron Corporation (Nasdaq: GERN) announced an upsized underwritten public offering of 55,876,297 shares at $2.45 each and pre-funded warrants for 25,000,000 shares at $2.449 each. The expected gross proceeds are approximately $198.1 million, aimed at funding preparatory activities for the potential U.S. commercial launch of imetelstat in lower risk MDS. The offering is set to close around January 10, 2023, pending customary conditions.

Geron Corporation (Nasdaq: GERN) announced a proposed public offering of $175 million in common stock, with an option for underwriters to buy an additional 15%. The offering is dependent on market conditions and does not guarantee completion. Goldman Sachs & Co. LLC and Stifel serve as joint book-running managers. A preliminary prospectus will be filed with the SEC. Geron focuses on developing therapies for hematologic malignancies, primarily its investigational telomerase inhibitor, imetelstat.

Geron Corporation (NASDAQ: GERN) announced positive results from its IMerge Phase 3 trial of imetelstat in patients with lower risk myelodysplastic syndromes (MDS). The trial met its primary endpoint of 8-week transfusion independence (TI) and a key secondary endpoint at 24 weeks, demonstrating significant benefits compared to placebo. Notably, the median TI duration was nearly one year for 8-week responders and 1.5 years for 24-week responders. No new safety signals were observed, and the company plans for U.S. and EU regulatory submissions in 2023, aiming for a commercial launch in 2024.

Geron Corporation (NASDAQ: GERN) will host a conference call on January 4, 2023, at 8:00 a.m. ET to discuss top-line results from the IMerge Phase 3 clinical trial of imetelstat for lower risk myelodysplastic syndromes (MDS). Investors can access the call via a live webcast on Geron’s website. Imetelstat is a first-in-class telomerase inhibitor aimed at treating hematologic malignancies. This trial represents a significant step in evaluating the drug's potential to impact patients' lives.